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Abstract
Postnatal permanent childhood hearing impairment (PCHI) is frequent (0.25%–0.99%) and difficult to detect in the early
stage, which may impede the speech, language and cognitive development of affected children. Genetic tests of common
variants associated with postnatal PCHI in newborns may provide an efficient way to identify those at risk. In this study, we
detected a strong association of the p.V37I exclusive genotype of GJB2 with postnatal PCHI in Chinese Hans (P=1.4610
210;
OR 62.92, 95% CI 21.27–186.12). This common genotype in Eastern Asians was present in a substantial percentage (20%) of
postnatal PCHI subjects, and its prevalence was significantly increased in normal-hearing newborns who failed at least one
newborn hearing screen. Our results indicated that the p.V37I exclusive genotype of GJB2 may cause subclinical hearing
impairment at birth and increases risk for postnatal PCHI. Genetic testing of GJB2 in East Asian newborns will facilitate
prompt detection and intervention of postnatal PCHI.
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Introduction
Hearing is critical for normal development and acquisition of
speech. Early detection with intervention and habilitation for
permanent childhood hearing impairment (PCHI) leads to
significantly better speech, language and cognitive development
[1,2,3]. While universal newborn hearing screening (NHS) has
been successful in detection of hearing impairment at birth, early
detection of postnatal PCHI, which occurs at an estimated
prevalence of 0.25%–0.99% in children aged 9 years [4,5],
remains a challenge [6]. A series of risk factors, featuring the
clinical, family or medical history, has been recommended by the
Joint Committee on Infant Hearing to prompt continued
audiological monitoring of those at higher risk of postnatal PCHI
[7]. These risk factors, however, were not present in a significant
percentage (52%–67.5%) of children with postnatal PCHI in
several previous reports [5,8].
Genetic testing in newborns has been proposed as a potentially
effective way to detect postnatal PCHI that are either not present
at birth or associated with subclinical hearing loss [6]. This
practice, however, is hindered by limited knowledge of common
genetic variants associated with postnatal PCHI. Mutations in the
GJB2 gene are the most common genetic cause for deafness
[9,10,11]. Though most cases of GJB2-associated hearing
impairment are congenital, a small number of individuals with
bi-allelic GJB2 mutations have been reported who initially passed
the NHS but were subsequently identified with hearing loss in
their infancy or early childhood [12,13]. No GJB2 mutation,
however, has been reported specifically associated with postnatal
PCHI.
The p.V37I mutation of GJB2 is highly prevalent in East Asians,
with a allele frequency of 4.3% in Thai [14], 1.0% in Japanese
[15], 0.6% in Korean [16], and 6.2% in Chinese (determined in
this study). When present in homozygosity or in compound
heterozygosity with another truncating mutation of GJB2 (referred
as ‘‘the exclusive p.V37I genotype’’ because only the p.V37I
allele(s) have the potential to produce protein product), it can lead
to non-fully penetrant, mild-to-moderate hearing impairment that
is sometimes progressive [17,18]. In this study, we hypothesized
that the p.V37I exclusive genotype of GJB2 is associated with
postnatal PCHI and serves as a genetic risk-indicator for PCHI.
Methods
Subjects and ethics statement
A total of 45 unrelated Chinese Han children with bilateral
postnatal PCHI (mean age of 7 years, 95% CI 3.9–10.1 years)
were recruited from Shanghai, China. Among them, fourteen
children (group 1) passed the NHS in both ears but developed
bilateral postnatal PCHI (mean hearing threshold 51.3 dB nHL,
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children were identified and recruited though a large scale
preschool hearing screen conducted by the Xinhua Hospital and
the Shanghai Child Health Care Institute during year 2009–2010,
and the remaining four through their clinic visits to the Xinhua
Hospital. Thirty-one children (group 2) did not receive NHS at
birth but passed the pediatric hearing tests of their kindergarten
enrollment physical examination at the age of 2–4 years. All these
31 children developed bilateral PCHI (mean hearing threshold
50.6 dB nHL, 95% CI 40.8–60.4 dB nHL) before age 9 years and
were recruited clinically through Xinhua Hospital.
A total of 1516 Chinese Han newborns were recruited from
Putuo Women and Children Hospital, Shanghai during 2009.
Follow-up of their NHS results showed that 1405 newborns passed
the initial hearing screen, 99 newborns failed the initial screen but
passed the repeat screen, and 12 newborns failed both screens
(Hearing diagnostic results unknown). We also recruited 173
Chinese Han infants who failed both NHSs but were subsequently
diagnosed as normal hearing (hearing threshold ,35 dB nHL in
both ears and passed all comprehensive auditory evaluation in the
referral hearing diagnosis conducted within six months of age)
from the Shanghai Children’s Medical Center, one of the major
Children Hearing Impairment Diagnosis Centers in Shanghai.
All subjects or their parents gave written, informed consent to
participate in this study. This study was approved by the Ethics
Committee of the Shanghai Jiaotong University School of
Medicine, Xinhua Hospital and was in compliance with the
Declaration of Helsinki.
Hearing screens and audiological evaluation
The newborn hearing screening of the subjects in this study
were preformed uniformly through the Universal Newborn
Hearing Screening Program (UNHSP) in Shanghai following
standardized testing criteria and procedures as previously decribed
[19]. This city-wide screening program was promoted and
legislated by the municipal government and was performed as
a hospital based, two-stage screening procedure since 2002.
Newborns were initially screened on Day 3 post-birth by the
transient-evoked otoacoustic emission (TEOAE), and those testing
positive underwent a repeat outpatient screening on Day 42.
Infants failed both screens were referred for audiological
evaluation at one of the Children Hearing Impairment Diagnosis
Centers in Shanghai. Diagnostic process for hearing loss in
newborns included otoscope examination, tympanometry, auto-
mated auditory brainstem response (AABR), distortion products
otoacoustic emission (DPOAE), auditory steady-state response
(ASSR) and behavior hearing test.
Hearing tests of the pre-kindergarten children in Shanghai were
routinely performed during their kindergarten enrollment physical
examination by the Shanghai Child Health Care Institute using
pediatric audiometers. In this study, a large scale preschool
hearing screens were also performed in 21427 children between
age 3 and 6 years in Shanghai by the Xinhua Hospital and the
Shanghai Child Health Care Institute between October 2009 and
September 2010 as previously described [20]. Pediatric audiom-
etry testing was uniformly carried out using the DK-5610 Assens
(Interacoustics A/S, Denmark) device. Each child was tested under
frequencies of 1, 2, and 4 kHz at 20 dB HL for three times. A pass
result was given if the child’s responses were judged to be clinically
reliable for at least two times for each frequency. This pediatric
audiometry testing was deemed sensitive as preschool children
with mild hearing impairment (25–40 dB HL) can be consistently
detected using this method in our previous study [20]. Those who
failed the initial preschool screen were re-tested one month later.
Children who failed both tests were referred to Xinhua Hospital
for detailed audiological evaluation.
Audiological evaluations were performed for all subjects with
postnatal PCHI, including otoscope examination, tympanometry,
pure tone audiometry (PTA), play PTA, visual reinforcement
audiometry and auditory brainstem response (ABR). Children
with conductive hearing impairment due to otitis media with
effusion (OME) and eustachian tube dysfunction were excluded for
further study. Mean hearing threshold was calculated by pure tone
averages in the better ear at 0.5, 1, 2 and 4 kHz. Bilateral
permanent childhood hearing impairment (PCHI) was defined as
mean hearing threshold exceeded 40 dB HL [4,5].
Genetic and statistical analysis
Genetic and statistical analyses of the study were performed in
the Molecular Biology of Hearing and Deafness Research
Laboratory, Xinhua Hospital. Genomic DNA was extracted from
either whole blood samples or fresh buccal swab samples.
Mutation screening of the GJB2 gene was performed by PCR
amplification and bidirectional sequencing as previously described
[21]. The p.V37I exclusive genotype of GJB2 was defined as either
homozygosity of p.V37I or compound heterozygosity of p.V37I
and another GJB2 truncating mutation. Fisher’s exact test and the
odds ratio calculation were used to compare the prevalence of the
p.V37I exclusive genotype of GJB2 among different subject
groups. P values were presented as the result of two-tailed analysis.
Table 1. Genotyping results of GJB2 in control and subject groups.
Catagory Total 2/2 p.V37I/2 c.235delC/2 T
*/2 p.V37I/p.V37I p.V37I/c.235delC
Control newborns 1516 1303 175 22 10 5 1
Postnatal PCHI group 1 14 7 0 2 2 3 0
Postnatal PCHI group 2 31 22 3 0 0 4 2
Newborns passed the
initial hearing screen
1405 1213 160 21 9 1 1
Newborns passed the
repeat hearing screen
99 83 12 1 1 2 0
Newborns passed the
referral diagnosis
173 132 21 8 2 8 2
*T: Other truncating GJB2 mutations identified in this study including c.299_300delAT, c.176del16 and c.507insAACG.
doi:10.1371/journal.pone.0036621.t001
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Association of the GJB2 p.V37I exclusive genotype with
postnatal PCHI
Mutation screening of GJB2 was performed in 45 Chinese Han
children with postnatal PCHI and 1516 ethnically-matched
control newborns (Table 1). From controls, we determined the
allele frequency of the p.V37I mutation as 6.2% (187/3032),
followed by that of c.235delC as 0.8% (23/3032). Consistent with
this result, homozygosity of p.V37I (5 in 1516 newborns) and
compound heterozygosity of p.V37I/c.235delC (1 in 1516 new-
borns) were the only two bi-allelic mutant genotypes of GJB2
observed in this study (termed as the p.V37I exclusive genotype as
p.V37I is the only non-truncating allele of GJB2).
The prevalence of the p.V37I exclusive genotype of GJB2 was
21.4% (3/14) in postnatal PCHI group 1 who passed NHS at
birth, and 19.4% (6/31) in postnatal PCHI group 2 who passed
the pediatric hearing tests during their kindergarten enrollment
physical examination, both significantly higher than the preva-
lence of 0.4% (6/1516) in the ethnically matched control
newborns (P=9.0610
25, OR=68.63, 95% CI 5.20–309.93 for
group1; P=9.8610
28, OR=60.40, 95% CI 18.22–200.27 for
group 2; P=1.4610
210, OR=62.92, 95% CI 21.27–186.12 for
the combined postnatal PCHI group, Table 2). These results
showed that the p.V37I exclusive genotype of GJB2 is strongly
associated with postnatal PCHI and is present in a substantial
percentage (20.0%, 9/45) of postnatal PCHI cases in Chinese.
Increased prevalence of the p.V37I exclusive genotype in
newborns with subclinical hearing loss
The 1516 control newborns can be categorized into three sub-
groups based on their NHS results: 1405 newborns who passed the
initial screen (sub-group 1), 99 newborns who failed the initial
screen but passed the repeat screen (sub-group 2), and 12
newborns who failed both screens (sub-group 3). The prevalence
of the p.V37I exclusive genotype was 2.0% (2/99) in sub-group 2,
significantly higher than the prevalence of 0.14% (2/1405) in sub-
group 1 (P=0.024, Table 3). Because of the small sample size and
the unavailability of the hearing diagnostic results of sub-group 3,
we separately recruited 173 newborns that failed both NHS tests
but were diagnosed with normal hearing on their referral
evaluations. The prevalence of the p.V37I exclusive genotype
was 5.8% (10/173) in this group, further higher than that in sub-
group 1 (P=1.7610
28). The increased prevalence of the p.V37I
exclusive genotype in normal-hearing newborns who failed at least
one NHS suggested that the p.V37I exclusive genotype causes
subclinical or borderline slight hearing loss at birth and increases
risk for postnatal PCHI.
Discussion
Our study identified the p.V37I exclusive genotype of GJB2 as
a common genetic risk-indicator of postnatal PCHI in Chinese
Han population. This genotype has been shown associated with
mild-to-moderate, sometimes progressive hearing impairment in
patients with various ages. Protein expression study also confirmed
that unlike other truncating mutations of GJB2 that are associated
with severer hearing impairment and lead to abnormal subcellular
localization of the mutant protein, the p.V37I mutant protein has
normal membrane expression as the wild type protein, suggesting
its retaining of at least part of the protein function [22]. The
clinical phenotype of the p.V37I mutation fits its potential role in
postnatal PCHI well as most late-onset sensorineural hearing
impairment is progressive and is not as severe as the congenital
hearing impairment. In this study, we found that the p.V37I
exclusive genotype is strongly associated with postnatal PCHI
(P=1.4610
210) and is present in a substantial percentage (20.0%)
of children with postnatal PCHI (Table 2). Homozygosity of
p.V37I is the primary p.V37I exclusive genotype, which was
present in 3.3% (5/1516) of control newborns and 15.6% (7/45)
of children with postnatal PCHI (Table 1). Although p.V37I/
c.235delC, which was present in 0.66% (1/1516) of control
newborns and 4.4% (2/45) of children with postnatal PCHI, is the
only other biallelic mutant genotype of GJB2 observed in our
study, compound heterozygous mutations of p.V37I and one other
truncating mutation of GJB2 should also be considered as a genetic
risk for postnatal PCHI due to their similar molecular pathogen-
esis mechanism.
Among newborns with the p.V37I exclusive genotype, it
remains unclear what percentage will develop PCHI congenitally
and what percentage will develop PCHI postnatally. However, our
study showed that even in those who were ‘‘cleared’’ during NHS
or referral hearing diagnosis (In the UNHS program in China,
referred newborns with hearing threshold lower than 35 dB nHL
for both ears were usually cleared as normal hearing without
further intervention.), the p.V37I exclusive genotype may still
cause subclinical or borderline slight hearing loss at birth and
increase the risk for postnatal PCHI, as prevalence of the p.V37I
exclusive genotype increased significantly in normal-hearing
newborns who failed at least one NHS (Table 3). Therefore
newborns with the p.V37I exclusive genotype represent a genet-
ically distinct group that is predisposed to mild, sometimes
subclinical hearing loss at birth, and this hearing loss may progress
and become apparent at later stage.
Based on these results, we propose that wide-spread genetic
testing for the GJB2 p.V37I exclusive genotype is warranted in
East Asian newborns. This screening can be performed either
universally in all newborns or preferentially in those who fail at
least one NHS. One of the interesting findings in this study is the
increased frequency of the p.V37I exclusive genotype in newborn
Table 2. Prevalence of the p.V37I exclusive genotype in control newborns and children with postnatal PCHI.
Total Exclusive p.V37I genotype (%) p- value
*
Control newborns 1516 6 (0.40) -
Postnatal PCHI group 1 14 3 (21.4) 9.0610
25
Postnatal PCHI group 2 31 6 (19.4) 9.8610
28
Combined postnatal PCHI group 45 9 (20.0) 1.4610
210
*Calculated by Fisher’s exact test, two tailed analysis in comparison to control newborns.
doi:10.1371/journal.pone.0036621.t002
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initial NHS. It will be important to study whether the former
newborns have a higher likelihood to develop postnatal PCHI. If
this turns out to be the case, then different strategies for
incorporating genetic testing into NHS should be evaluated to
identify which strategy would be optimal.
In summary, our study revealed a strong association of PCHI
with the p.V37I exclusive genotype of GJB2. We also found that
the prevalence of this genotype increased significantly in normal-
hearing newborns who failed at least one newborn hearing screen.
Based on these results, we concluded that the p.V37I exclusive
genotype of GJB2 causes subclinical hearing loss at birth and
increases risk for postnatal PCHI. Our study may form basis to
support wide-spread genetic test of the p.V37I exclusive genotype
of GJB2 in East Asian newborns. Continued audiologic monitor-
ing should be offered to children who carry this genetic variant to
facilitate prompt detection and intervention of postnatal PCHI,
which in turn will benefit the speech, language and cognitive
development of the affected children.
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